Aon Expands Data Center Insurance to $2.5B, GLP-1 Study Reveals 47% Drop in Female Cardiovascular Hospitalizations

AONAON

Aon expanded its Data Center Lifecycle Insurance Program by $1 billion to $2.5 billion capacity, integrating construction, cyber and cargo coverage for AI-driven data centers. Its GLP-1 research shows 47% fewer female major cardiovascular hospitalizations and up to nine-point lower employer medical cost growth with at least 80% therapy adherence.

1. Aon Boosts Data Center Lifecycle Insurance Capacity to $2.5 Billion

Aon has expanded its proprietary Data Center Lifecycle Insurance Program (DCLP) by $1 billion, bringing total capacity to $2.5 billion to address surging investment in cloud computing, artificial intelligence and digital infrastructure. Initially launched in 2025, DCLP now provides up to $2.5 billion in combined coverage for Construction All Risks, Delay in Start-Up and Operational Property Damage/Business Interruption, alongside $400 million for cyber and tech errors & omissions, $100 million for third-party liability (excluding U.S. exposures) and $500 million for project cargo. By unifying construction, cyber, cargo and operational risks into a single multi-line solution and complementing capacity with Aon’s integrated risk engineering and analytics, the program aims to help investors, developers and operators secure large-scale capacity, accelerate project execution and strengthen operational continuity across the full data center lifecycle.

2. Study Shows GLP-1 Use Cuts Employer Healthcare Costs and Women’s Cancer Incidence

Aon’s updated analysis of U.S. commercial health claims data for more than 192,000 GLP-1 therapy users reveals long-term clinical and financial benefits for employers. Female users experienced a 47% reduction in hospitalizations for major adverse cardiovascular events and approximately 50% lower incidence of ovarian cancer and 14% lower incidence of breast cancer compared with non-users. From July 2022 to March 2025, medical cost growth among GLP-1 users was six percentage points lower than non-users at 30 months—and nine points lower for those maintaining at least 80% adherence. Weight-loss indications yielded three and seven percentage-point reductions in cost growth at 18 months for general users and high-adherence users, respectively. With GLP-1 therapies comprising around 20% of total prescription drug spend and rising 50% in 2025, these findings underscore the importance of adherence-focused programs to help employers manage an expected 9.5% increase in underlying U.S. healthcare costs this year.

Sources

PP